DK1624871T3 - Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger - Google Patents

Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger

Info

Publication number: DK1624871T3
Authority: DK; Denmark
Prior art keywords: dyslipidemia; pharmaceutical compositions; related conditions; treating atherosclerosis; atherosclerosis
Prior art date: 2003-05-15

Application number

DK04785539T

Other languages

Danish (da)

English (en)

Inventor

Kang Cheng

M Gerard Waters

Kathleen M Metters

Gary O'neill

Original Assignee

Merck & Co Inc

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2004-05-13

Publication date

2009-11-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1624871(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-13 Application filed by Merck & Co Inc, Merck Frosst Canada Ltd filed Critical Merck & Co Inc

2009-11-16 Application granted granted Critical

2009-11-16 Publication of DK1624871T3 publication Critical patent/DK1624871T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DK04785539T 2003-05-15 2004-05-13 Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger DK1624871T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47066503P	2003-05-15	2003-05-15
PCT/US2004/014980 WO2004103370A1 (en)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
DK1624871T3 true DK1624871T3 (da)	2009-11-16

Family

ID=33476734

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK09163448.5T DK2116244T3 (da)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions
DK04785539T DK1624871T3 (da)	2003-05-15	2004-05-13	Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK09163448.5T DK2116244T3 (da)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions

Country Status (44)

Country	Link
US (4)	US20040229844A1 (es)
EP (3)	EP2116244B1 (es)
JP (2)	JP4637833B2 (es)
KR (2)	KR100960749B1 (es)
CN (3)	CN101559227B (es)
AR (1)	AR041089A1 (es)
AU (2)	AU2004240597B2 (es)
BR (1)	BRPI0410273A (es)
CA (1)	CA2525772C (es)
CL (1)	CL2004001056A1 (es)
CO (1)	CO5630034A2 (es)
CR (2)	CR8047A (es)
CY (2)	CY1109476T1 (es)
DE (1)	DE602004022036D1 (es)
DK (2)	DK2116244T3 (es)
DO (1)	DOP2004000907A (es)
EA (2)	EA011895B1 (es)
EC (1)	ECSP056156A (es)
ES (2)	ES2328148T3 (es)
GE (2)	GEP20084569B (es)
GT (1)	GT200400098A (es)
HN (1)	HN2004000171A (es)
HR (2)	HRP20090424T1 (es)
IL (1)	IL171962A (es)
IS (1)	IS2708B (es)
JO (1)	JO2564B1 (es)
MA (1)	MA27835A1 (es)
ME (1)	MEP60108A (es)
MX (1)	MXPA05012272A (es)
MY (1)	MY140639A (es)
NO (1)	NO20055957L (es)
NZ (2)	NZ543399A (es)
PA (1)	PA8603201A1 (es)
PE (1)	PE20050552A1 (es)
PL (2)	PL1624871T3 (es)
PT (2)	PT1624871E (es)
RS (3)	RS20120498A1 (es)
SG (1)	SG153667A1 (es)
SI (2)	SI2116244T1 (es)
TN (1)	TNSN05290A1 (es)
TW (2)	TWI334354B (es)
UA (1)	UA89615C2 (es)
WO (1)	WO2004103370A1 (es)
ZA (1)	ZA200508288B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002094830A2 (en) *	2001-05-23	2002-11-28	Merck Frosst Canada & Co.	DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
WO2004083388A2 (en) *	2003-03-14	2004-09-30	Bristol-Myers Squibb Company	Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
DK1799196T3 (en)	2004-10-08	2016-08-15	Forward Pharma As	Controlled release pharmaceutical compositions comprising a fumaric acid ester
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006078776A2 (en) *	2005-01-19	2006-07-27	The Trustees Of The University Of Pennsylvania	Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
JP2008530250A (ja) *	2005-02-17	2008-08-07	メルクエンドカムパニーインコーポレーテッド	アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
JP2008538277A (ja) *	2005-02-18	2008-10-23	アリーナファーマシューティカルズ，インコーポレイテッド	脂質関連障害の治療用の組成物および方法
US7750015B2 (en) *	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006124490A2 (en) *	2005-05-17	2006-11-23	Schering Corporation	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
EP1942905A4 (en) *	2005-08-29	2010-04-07	Merck Sharp & Dohme	AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
CN101305010A (zh) *	2005-09-01	2008-11-12	阿雷生物药品公司	Raf抑制剂化合物及其用法
EP1940382A2 (en) *	2005-10-07	2008-07-09	Aditech Pharma AB	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
AU2006331770A1 (en) *	2005-12-21	2007-07-05	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
CN101378807A (zh) *	2005-12-21	2009-03-04	先灵公司	H3拮抗剂/反相激动剂与食欲抑制剂的组合
WO2007087204A2 (en) *	2006-01-20	2007-08-02	Schering Corpooration	Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
US20090069275A1 (en) *	2006-02-17	2009-03-12	Rocca Jose G	Low flush niacin formulation
CA2663503A1 (en) *	2006-09-15	2008-03-20	Schering Corporation	Azetidinone derivatives and methods of use thereof
US20080070890A1 (en) *	2006-09-15	2008-03-20	Burnett Duane A	Spirocyclic Azetidinone Compounds and Methods of Use Thereof
MX2009002921A (es) *	2006-09-15	2009-04-01	Schering Corp	Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
WO2008039882A1 (en) *	2006-09-30	2008-04-03	Sanofi-Aventis U.S. Llc	A combination of niacin and a prostaglandin d2 receptor antagonist
EP2114154B1 (en) *	2007-02-08	2013-08-28	Merck Sharp & Dohme Corp.	Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
CN101559058B (zh) *	2008-04-16	2011-07-20	北京本草天源药物研究院	一种治疗血脂异常的药物组合物
WO2009142731A2 (en) *	2008-05-20	2009-11-26	Cerenis Therapeutics S.A.	Niacin and nsaid combination therapy
US8507473B2 (en)	2008-09-11	2013-08-13	Arena Pharmaceuticals, Inc.	3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2341773A4 (en) *	2008-09-24	2012-03-07	Merck Sharp & Dohme	PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
EP2379562A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
CN109044985A (zh)	2009-01-09	2018-12-21	前进制药知识产权有限公司	包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
WO2011115943A1 (en)	2010-03-16	2011-09-22	Aventis Pharmaceuticals Inc.	A substituted pyrimidine as a prostaglandin d2 receptor antagonist
KR20130018770A (ko)	2010-03-16	2013-02-25	아벤티스 파마슈티칼스 인크.	프로스타글란딘 ｄ２ 수용체 길항제들로서의 치환된 피리미딘들
WO2016128565A1 (en)	2015-02-13	2016-08-18	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
JPS6352514B2 (es)	1977-09-30	1988-10-19	Rca Corp
US4342767A (en)	1980-01-23	1982-08-03	Merck & Co., Inc.	Hypocholesteremic fermentation products
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es)	1980-06-06	1987-04-10	Sankyo Co	Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
US5190972A (en) *	1992-01-27	1993-03-02	The University Of Melbourne	Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0821587A4 (en) *	1995-04-19	1999-05-19	Lipoprotein Technologies Inc	COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION
EP0877750B1 (en)	1995-10-31	2002-06-19	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
WO1997016424A1 (en)	1995-11-02	1997-05-09	Schering Corporation	Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
PT814782E (pt)	1995-12-22	2003-04-30	Nissan Chemical Ind Ltd	Composicao farmaceutica estabilizada com um agente basico
US5886171A (en)	1996-05-31	1999-03-23	Schering Corporation	3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en)	1996-05-31	1998-04-14	Schering Corporation	3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en)	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
EP1017390B1 (en) *	1997-07-31	2007-04-18	Kos Life Sciences, Inc.	Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
US6469035B1 (en) *	1997-07-31	2002-10-22	Eugenio A. Cefali	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20010006644A1 (en) *	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
BR9812770A (pt) *	1997-10-27	2000-12-12	Reddy Research Foundation	Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
US6133001A (en)	1998-02-23	2000-10-17	Schering Corporation	Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en)	1998-10-02	1999-07-06	Schering Corporation	Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
AR025144A1 (es)	1998-12-07	2002-11-13	Schering Corp	Proceso para preparar azetidinonas, proceso para preparar compuestos intermediarios asi como dichos compuestos intermediarios
EA200100704A1 (ru)	1998-12-23	2002-02-28	Джи.Ди.Сирл Ллс	Комбинация для применения по сердечно-сосудистым показаниям
CA2367289C (en)	1999-04-05	2008-02-12	Schering Corporation	Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
AU4343500A (en)	1999-04-16	2000-11-02	Schering Corporation	Use of azetidinone compounds
IT1306141B1 (it) *	1999-05-17	2001-05-30	Giampiero Valletta	Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
HUP0301493A2 (hu)	2000-03-09	2003-08-28	Ono Pharmaceutical Co., Ltd.	Indolszármazékok, eljárás előállításukra és alkalmazásuk
US20010047027A1 (en) *	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
JP2002008186A (ja) *	2000-06-23	2002-01-11	Mitsubishi Heavy Ind Ltd	車種識別装置
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) *	2000-09-13	2007-03-07	三洋電機株式会社	映像信号処理回路
AU2002242910A1 (en)	2001-04-11	2002-10-28	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
WO2002094830A2 (en) *	2001-05-23	2002-11-28	Merck Frosst Canada & Co.	DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
CA2459515A1 (en)	2001-09-07	2003-03-20	Kazuhiko Torisu	Indole derivatives
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7351705B2 (en) *	2002-03-19	2008-04-01	Ono Pharmaceutical Co., Ltd.	Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient
DE60326232D1 (de) *	2002-06-03	2009-04-02	Novartis Ag	Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) *	2005-07-01	2008-08-06	タキゲン製造株式会社	ステー

2004
- 2004-05-05 AR ARP040101527A patent/AR041089A1/es unknown
- 2004-05-06 JO JO200454A patent/JO2564B1/en active
- 2004-05-06 PE PE2004000463A patent/PE20050552A1/es not_active Application Discontinuation
- 2004-05-10 MY MYPI20041729A patent/MY140639A/en unknown
- 2004-05-13 BR BRPI0410273-8A patent/BRPI0410273A/pt not_active IP Right Cessation
- 2004-05-13 AU AU2004240597A patent/AU2004240597B2/en not_active Ceased
- 2004-05-13 RS RS20120498A patent/RS20120498A1/sr unknown
- 2004-05-13 UA UAA200512018A patent/UA89615C2/ru unknown
- 2004-05-13 EP EP09163448A patent/EP2116244B1/en not_active Expired - Lifetime
- 2004-05-13 SI SI200431951T patent/SI2116244T1/sl unknown
- 2004-05-13 MX MXPA05012272A patent/MXPA05012272A/es active IP Right Grant
- 2004-05-13 CN CN2008101690579A patent/CN101559227B/zh not_active Expired - Fee Related
- 2004-05-13 RS YU20050777A patent/RS52731B/sr unknown
- 2004-05-13 KR KR1020077029888A patent/KR100960749B1/ko not_active Expired - Fee Related
- 2004-05-13 GE GEAP20049114A patent/GEP20084569B/en unknown
- 2004-05-13 EP EP04785539A patent/EP1624871B1/en not_active Expired - Lifetime
- 2004-05-13 ES ES04785539T patent/ES2328148T3/es not_active Expired - Lifetime
- 2004-05-13 PT PT04785539T patent/PT1624871E/pt unknown
- 2004-05-13 EP EP10182413A patent/EP2286816A1/en not_active Withdrawn
- 2004-05-13 CA CA2525772A patent/CA2525772C/en not_active Expired - Fee Related
- 2004-05-13 KR KR1020057021795A patent/KR100806008B1/ko not_active Expired - Lifetime
- 2004-05-13 RS RS20120499A patent/RS20120499A1/sr unknown
- 2004-05-13 JP JP2006515355A patent/JP4637833B2/ja not_active Expired - Fee Related
- 2004-05-13 PL PL04785539T patent/PL1624871T3/pl unknown
- 2004-05-13 PT PT09163448T patent/PT2116244E/pt unknown
- 2004-05-13 GT GT200400098A patent/GT200400098A/es unknown
- 2004-05-13 EA EA200702674A patent/EA011895B1/ru not_active IP Right Cessation
- 2004-05-13 PL PL09163448T patent/PL2116244T3/pl unknown
- 2004-05-13 DK DK09163448.5T patent/DK2116244T3/da active
- 2004-05-13 SI SI200431221T patent/SI1624871T1/sl unknown
- 2004-05-13 SG SG200708456-9A patent/SG153667A1/en unknown
- 2004-05-13 WO PCT/US2004/014980 patent/WO2004103370A1/en not_active Ceased
- 2004-05-13 HR HR20090424T patent/HRP20090424T1/xx unknown
- 2004-05-13 CN CN2012100149106A patent/CN102526735A/zh active Pending
- 2004-05-13 US US10/844,773 patent/US20040229844A1/en not_active Abandoned
- 2004-05-13 ES ES09163448T patent/ES2392743T3/es not_active Expired - Lifetime
- 2004-05-13 CN CNB2004800128531A patent/CN100441184C/zh not_active Expired - Fee Related
- 2004-05-13 ME MEP-601/08A patent/MEP60108A/xx unknown
- 2004-05-13 DE DE602004022036T patent/DE602004022036D1/de not_active Expired - Lifetime
- 2004-05-13 DK DK04785539T patent/DK1624871T3/da active
- 2004-05-13 GE GEAP200410277A patent/GEP20105025B/en unknown
- 2004-05-13 NZ NZ543399A patent/NZ543399A/en not_active IP Right Cessation
- 2004-05-13 EA EA200501817A patent/EA009744B1/ru not_active IP Right Cessation
- 2004-05-13 NZ NZ572515A patent/NZ572515A/en not_active IP Right Cessation
- 2004-05-14 CL CL200401056A patent/CL2004001056A1/es unknown
- 2004-05-14 DO DO2004000907A patent/DOP2004000907A/es unknown
- 2004-05-14 TW TW093113730A patent/TWI334354B/zh not_active IP Right Cessation
- 2004-05-14 TW TW096125297A patent/TWI341199B/zh not_active IP Right Cessation
- 2004-05-14 HN HN2004000171A patent/HN2004000171A/es unknown
- 2004-05-14 PA PA20048603201A patent/PA8603201A1/es unknown
2005
- 2005-10-13 ZA ZA200508288A patent/ZA200508288B/xx unknown
- 2005-10-13 IS IS8071A patent/IS2708B/is unknown
- 2005-10-19 CR CR8047A patent/CR8047A/es unknown
- 2005-11-09 MA MA28589A patent/MA27835A1/fr unknown
- 2005-11-10 CO CO05114676A patent/CO5630034A2/es active IP Right Grant
- 2005-11-11 EC EC2005006156A patent/ECSP056156A/es unknown
- 2005-11-14 TN TNP2005000290A patent/TNSN05290A1/en unknown
- 2005-11-14 IL IL171962A patent/IL171962A/en not_active IP Right Cessation
- 2005-12-14 NO NO20055957A patent/NO20055957L/no not_active Application Discontinuation
2008
- 2008-03-11 CR CR9808A patent/CR9808A/es not_active Application Discontinuation
2009
- 2009-05-21 US US12/470,049 patent/US20090233977A1/en not_active Abandoned
- 2009-10-13 CY CY20091101051T patent/CY1109476T1/el unknown
- 2009-11-30 US US12/627,787 patent/US20100076002A1/en not_active Abandoned
- 2009-12-02 JP JP2009274146A patent/JP2010077151A/ja active Pending
2011
- 2011-01-24 US US13/012,696 patent/US20110118292A1/en not_active Abandoned
- 2011-03-07 AU AU2011200986A patent/AU2011200986B2/en not_active Ceased
2012
- 2012-10-11 HR HRP20120818TT patent/HRP20120818T1/hr unknown
- 2012-11-05 CY CY20121101050T patent/CY1113342T1/el unknown

Also Published As

Publication number	Publication date
NZ543399A (en)	2009-02-28
SG153667A1 (en)	2009-07-29
CN101559227A (zh)	2009-10-21
EP2286816A1 (en)	2011-02-23
RS20120498A1 (sr)	2013-08-30
KR20060012617A (ko)	2006-02-08
IL171962A0 (en)	2006-04-10
KR100806008B1 (ko)	2008-02-26
AU2011200986A1 (en)	2011-03-31
CY1113342T1 (el)	2016-06-22
EA200702674A1 (ru)	2008-04-28
AU2011200986B2 (en)	2012-11-08
EA009744B1 (ru)	2008-04-28
RS20120499A1 (sr)	2013-08-30
US20110118292A1 (en)	2011-05-19
HRP20090424T1 (en)	2009-09-30
UA89615C2 (ru)	2010-02-25
PT2116244E (pt)	2012-11-02
IS2708B (is)	2011-01-15
JO2564B1 (en)	2010-11-03
EA200501817A1 (ru)	2006-06-30
MEP60108A (en)	2011-05-10
JP4637833B2 (ja)	2011-02-23
PT1624871E (pt)	2009-09-07
KR100960749B1 (ko)	2010-06-01
EP2116244A1 (en)	2009-11-11
TWI341199B (en)	2011-05-01
GEP20105025B (en)	2010-06-25
RS52731B (sr)	2013-08-30
KR20080003470A (ko)	2008-01-07
CN102526735A (zh)	2012-07-04
SI1624871T1 (sl)	2009-12-31
CY1109476T1 (el)	2014-08-13
PL2116244T3 (pl)	2013-01-31
TWI334354B (en)	2010-12-11
JP2006526030A (ja)	2006-11-16
CO5630034A2 (es)	2006-04-28
IL171962A (en)	2012-06-28
ES2328148T3 (es)	2009-11-10
HK1092722A1 (zh)	2007-02-16
GT200400098A (es)	2005-03-03
DOP2004000907A (es)	2004-11-30
CN1787819A (zh)	2006-06-14
ZA200508288B (en)	2008-08-27
PA8603201A1 (es)	2005-02-04
CR9808A (es)	2008-07-29
TW200503757A (en)	2005-02-01
AR041089A1 (es)	2005-05-04
AU2004240597B2 (en)	2011-01-06
NO20055957L (no)	2006-02-14
CR8047A (es)	2006-07-14
HRP20120818T1 (hr)	2012-11-30
RS20050777A (sr)	2008-04-04
CL2004001056A1 (es)	2005-03-28
ES2392743T3 (es)	2012-12-13
DE602004022036D1 (de)	2009-08-27
DK2116244T3 (da)	2012-11-26
MA27835A1 (fr)	2006-04-03
CN101559227B (zh)	2012-03-21
JP2010077151A (ja)	2010-04-08
CA2525772A1 (en)	2004-12-02
NZ572515A (en)	2010-07-30
US20100076002A1 (en)	2010-03-25
GEP20084569B (en)	2008-12-25
US20090233977A1 (en)	2009-09-17
US20040229844A1 (en)	2004-11-18
WO2004103370A1 (en)	2004-12-02
CA2525772C (en)	2011-03-15
MY140639A (en)	2010-01-15
PE20050552A1 (es)	2005-08-06
AU2004240597A1 (en)	2004-12-02
SI2116244T1 (sl)	2012-12-31
TNSN05290A1 (en)	2007-07-10
TW200803844A (en)	2008-01-16
EA011895B1 (ru)	2009-06-30
MXPA05012272A (es)	2006-05-19
EP1624871A1 (en)	2006-02-15
BRPI0410273A (pt)	2006-05-16
ECSP056156A (es)	2006-04-19
HN2004000171A (es)	2011-07-11
EP2116244B1 (en)	2012-08-08
IS8071A (is)	2005-10-13
PL1624871T3 (pl)	2009-12-31
CN100441184C (zh)	2008-12-10
EP1624871B1 (en)	2009-07-15

Publication	Publication Date	Title
DK1624871T3 (da)	2009-11-16	Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
DK1667986T3 (da)	2013-05-06	Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1628530T3 (da)	2012-07-23	Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK3159357T3 (da)	2022-04-04	Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner
DK1891571T3 (da)	2013-10-28	Hæmning af spredning af uønskede koder og data
NO20052547D0 (no)	2005-05-26	System og fremgangsmate for foretrukken applikasjonsinstallasjon og -eksekvering.
DK1550535T3 (da)	2020-01-27	Fremgangsmåde og indretning til fremstilling af betonmasse
DK1644021T3 (da)	2012-10-29	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1791791T3 (da)	2019-08-26	Fremgangsmåder og sammensætninger til behandling af vand
DK1587821T6 (da)	2025-05-26	Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
DK1499184T3 (da)	2013-01-02	Sammensætninger til behandling af ektoparasitangreb
DK1539115T3 (da)	2008-01-28	Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
DK1677735T3 (da)	2014-10-27	Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
DK1997512T3 (da)	2014-01-27	Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1673214T3 (da)	2013-07-15	Apparat og fremgangsmåde til behandling af slam
DK1596868T3 (da)	2008-12-08	Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1874557T3 (da)	2014-06-10	Identitetsdokument og fremgangsmåde til fremstilling deraf
DK2110135T3 (da)	2014-03-31	Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
DK1539200T3 (da)	2014-06-30	Fremgangsmåde til behandling af multipel sklerose
DK1883293T3 (da)	2010-09-20	Sammensætning og fremgangsmåde til kontrol af insekter
DK1478438T3 (da)	2012-08-27	Fremgangsmåder og sammensætninger til behandling af astma
DK1461047T3 (da)	2012-10-15	Sammensætninger og fremgangsmåde til behandling af dyr
DK1768489T3 (da)	2013-10-28	Apparat og fremgangsmåde til destruktion af vegetation
DK1599469T3 (da)	2006-10-09	Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1589973T3 (da)	2010-07-19	Formulering og fremgangsmåder til behandling af thrombocytæmi